Bavarian plans to send RSV vaccine to phase III, prepares equity raise
A commitment to initiate a phase III study of its vaccine candidate against the RS virus in the first half of 2022 has led Bavarian Nordic to prepare a share issue involving up to 10 percent of its registered capital.
by marketwire, translated by daniel pedersen
Bavarian Nordic has committed to initiating a phase III study of its vaccine against RSV in the first half of 2022. However, sufficient funding must first be secured through a fundraising round where 10 percent of registered share capital is up for grabs, the company reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic: We can adapt our vaccine if necessary
For subscribers
